295 related articles for article (PubMed ID: 20174579)
1. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.
Rohan LC; Moncla BJ; Kunjara Na Ayudhya RP; Cost M; Huang Y; Gai F; Billitto N; Lynam JD; Pryke K; Graebing P; Hopkins N; Rooney JF; Friend D; Dezzutti CS
PLoS One; 2010 Feb; 5(2):e9310. PubMed ID: 20174579
[TBL] [Abstract][Full Text] [Related]
2. Reformulated tenofovir gel for use as a dual compartment microbicide.
Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D
J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
[TBL] [Abstract][Full Text] [Related]
3. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.
Dezzutti CS; Shetler C; Mahalingam A; Ugaonkar SR; Gwozdz G; Buckheit KW; Buckheit RW
Antiviral Res; 2012 Nov; 96(2):221-5. PubMed ID: 22940075
[TBL] [Abstract][Full Text] [Related]
5. Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation.
Dezzutti CS; Russo J; Wang L; Abebe KZ; Li J; Friend DR; McGowan IM; Rohan LC
PLoS One; 2014; 9(7):e102585. PubMed ID: 25025306
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.
Dezzutti CS; Yandura S; Wang L; Moncla B; Teeple EA; Devlin B; Nuttall J; Brown ER; Rohan LC
Pharm Res; 2015 Nov; 32(11):3768-81. PubMed ID: 26078001
[TBL] [Abstract][Full Text] [Related]
7. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.
Cost M; Dezzutti CS; Clark MR; Friend DR; Akil A; Rohan LC
Antimicrob Agents Chemother; 2012 Jun; 56(6):3058-66. PubMed ID: 22430977
[TBL] [Abstract][Full Text] [Related]
8. Reverse transcriptase inhibitors as potential colorectal microbicides.
Herrera C; Cranage M; McGowan I; Anton P; Shattock RJ
Antimicrob Agents Chemother; 2009 May; 53(5):1797-807. PubMed ID: 19258271
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.
Gali Y; Delezay O; Brouwers J; Addad N; Augustijns P; Bourlet T; Hamzeh-Cognasse H; Ariën KK; Pozzetto B; Vanham G
Antimicrob Agents Chemother; 2010 Dec; 54(12):5105-14. PubMed ID: 20921308
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides.
Fletcher PS; Elliott J; Grivel JC; Margolis L; Anton P; McGowan I; Shattock RJ
AIDS; 2006 Jun; 20(9):1237-45. PubMed ID: 16816551
[TBL] [Abstract][Full Text] [Related]
11. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
Chaowanachan T; Krogstad E; Ball C; Woodrow KA
PLoS One; 2013; 8(4):e61416. PubMed ID: 23630586
[TBL] [Abstract][Full Text] [Related]
12. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
Ham AS; Ugaonkar SR; Shi L; Buckheit KW; Lakougna H; Nagaraja U; Gwozdz G; Goldman L; Kiser PF; Buckheit RW
J Pharm Sci; 2012 Apr; 101(4):1423-35. PubMed ID: 22227864
[TBL] [Abstract][Full Text] [Related]
13. Effects of tenofovir on cytokines and nucleotidases in HIV-1 target cells and the mucosal tissue environment in the female reproductive tract.
Biswas N; Rodriguez-Garcia M; Shen Z; Crist SG; Bodwell JE; Fahey JV; Wira CR
Antimicrob Agents Chemother; 2014 Nov; 58(11):6444-53. PubMed ID: 25136003
[TBL] [Abstract][Full Text] [Related]
14. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
[TBL] [Abstract][Full Text] [Related]
15. Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.
Chateau ML; Denton PW; Swanson MD; McGowan I; Garcia JV
PLoS One; 2013; 8(3):e60024. PubMed ID: 23527295
[TBL] [Abstract][Full Text] [Related]
16. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.
Nuttall J; Kashuba A; Wang R; White N; Allen P; Roberts J; Romano J
Antimicrob Agents Chemother; 2012 Jan; 56(1):103-9. PubMed ID: 21986823
[TBL] [Abstract][Full Text] [Related]
18. Design of tenofovir-UC781 combination microbicide vaginal gels.
Kiser PF; Mahalingam A; Fabian J; Smith E; Damian FR; Peters JJ; Katz DF; Elgendy H; Clark MR; Friend DR
J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
Férir G; Palmer KE; Schols D
Virology; 2011 Sep; 417(2):253-8. PubMed ID: 21802104
[TBL] [Abstract][Full Text] [Related]
20. Vaginal deployment and tenofovir delivery by microbicide gels.
Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF
Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
